Relapsed/Refractory Chronic Lymphocytic Leukemia: The Evolving Role of BTK Inhibitors

Keeping Current CME

English - December 06, 2023 19:21 - 28 minutes - 27.4 MB - ★★★★ - 22 ratings
Science Health & Fitness Medicine Homepage Download Apple Podcasts Google Podcasts Overcast Castro Pocket Casts RSS feed

Previous Episode: Personalizing Risk Assessment to Enhance Primary Cardiovascular Prevention: From Methods to Interpretation

Next Episode: Novel Biologic Therapies for Spondyloarthritis: The Year in Review

Did you know that the National Comprehensive Cancer Network (NCCN) guidelines now include an investigational noncovalent BTK inhibitor for the treatment of relapsed/refractory CLL?

Credit available for this activity expires: 12/05/24
Earn Credit / Learning Objectives & Disclosures:
https://www.medscape.org/viewarticle/998747?ecd=bdc_podcast_libsyn_mscpedu